Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 3/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16689289 | 0.84 | KDM4E (0.46) | SRCALDH1A1KDM4EUSP2AR | |
| SCHEMBL5652331 | 0.74 | SRC (0.46) | SRCALDH1A1KDM4EUSP2AR | |
| SCHEMBL20866202 | 0.74 | SRC (0.46) | SRCALDH1A1KDM4EUSP2AR | |
| SCHEMBL7336233 | 0.73 | KDM4E (0.52) | SRCALDH1A1KDM4EUSP2MAPK1 | |
| SCHEMBL6968151 | 0.73 | KDM4E (0.52) | SRCALDH1A1KDM4EUSP2MAPK1 | |
| SCHEMBL12284280 | 0.73 | AR (0.50) | ALDH1A1KDM4EARHPGDMAPK1 | |
| SCHEMBL13862091 | 0.72 | AR (0.39) | SRCALDH1A1KDM4EUSP2CFD | |
| SCHEMBL482053 | 0.71 | AR (0.42) | SRCALDH1A1KDM4EUSP2AR | |
| SCHEMBL28011680 | 0.71 | HTR2A (0.44) | SRCALDH1A1KDM4EUSP2HPGD | |
| SCHEMBL13862086 | 0.70 | AR (0.44) | SRCALDH1A1KDM4EUSP2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| EP-2864322-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | CFB, CFH, TFPI | SRC 4209/4885ALDH1A1 2221/4885KDM4E 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.